Patrón de metilación génico en el cáncer de mama

Background: Genomic DNA methylation, mutations and allelic deletions explain the inactivation of genes involved in cell proliferation and cell cycle control mechanisms. Aim: To analyze the methylation pattern of important genes related to different carcinogenic mechanisms in patients with breast can...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roa S,Juan Carlos, Anabalón R,Leonardo, Tapia E,Oscar, Martínez S,Javier, Araya O,Juan Carlos, Villaseca H,Miguel, Guzmán G,Pablo, Roa E,Iván
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2004
Materias:	Breast neoplasms CDKN2A protein DNA probes Genes P16
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000900007
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872004000900007
record_format	dspace
spelling	oai:scielo:S0034-988720040009000072005-11-22Patrón de metilación génico en el cáncer de mamaRoa S,Juan CarlosAnabalón R,LeonardoTapia E,OscarMartínez S,JavierAraya O,Juan CarlosVillaseca H,MiguelGuzmán G,PabloRoa E,Iván Breast neoplasms CDKN2A protein DNA probes Genes P16 Background: Genomic DNA methylation, mutations and allelic deletions explain the inactivation of genes involved in cell proliferation and cell cycle control mechanisms. Aim: To analyze the methylation pattern of important genes related to different carcinogenic mechanisms in patients with breast cancer and the relationship with its biological behavior. Material and methods: Seventy fresh-frozen breast cancer samples were selected. The methylation specific PCR (MSP) test was used to analyze promoter methylation status for genes CDKN2A (p16), hMLH1, APC, CDH1 (Cadherin E) and FHIT. Results: We found methylation in at least one of the genes studied in 88% of cases and in 3 or more genes in 40.5% of cases. The frequencies of promoter hypermethylation of CDKN2A, hMLH1, APC, CDH1 and FHIT were 41.4%, 11.4%, 52.9%, 70% y 42.9%, respectively. We found a relationship between CDKN2A methylation and better survival (p=0.002). CDH1 methylation and poor histological differentiation (p=0.007), hMLH1 methylation and non-Mapuche ethnicity (p=0.03), APC methylation and larger tumor size (p <0.05), FHIT methylation and lack of estrogen receptor IHC expression (p <0.05). Conclusions: The high frequency of promoter methylation in patients with breast cancer confirms its role in breast carcinogenesis. The finding of alterations in the methylation pattern of genes studied and its association with prognostic factors is a helpful tool in the search of new criteria for clinical and therapeutic decision making (Rev Méd Chile 2004; 132: 1069-77)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.132 n.9 20042004-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000900007es10.4067/S0034-98872004000900007
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Breast neoplasms CDKN2A protein DNA probes Genes P16
spellingShingle	Breast neoplasms CDKN2A protein DNA probes Genes P16 Roa S,Juan Carlos Anabalón R,Leonardo Tapia E,Oscar Martínez S,Javier Araya O,Juan Carlos Villaseca H,Miguel Guzmán G,Pablo Roa E,Iván Patrón de metilación génico en el cáncer de mama
description	Background: Genomic DNA methylation, mutations and allelic deletions explain the inactivation of genes involved in cell proliferation and cell cycle control mechanisms. Aim: To analyze the methylation pattern of important genes related to different carcinogenic mechanisms in patients with breast cancer and the relationship with its biological behavior. Material and methods: Seventy fresh-frozen breast cancer samples were selected. The methylation specific PCR (MSP) test was used to analyze promoter methylation status for genes CDKN2A (p16), hMLH1, APC, CDH1 (Cadherin E) and FHIT. Results: We found methylation in at least one of the genes studied in 88% of cases and in 3 or more genes in 40.5% of cases. The frequencies of promoter hypermethylation of CDKN2A, hMLH1, APC, CDH1 and FHIT were 41.4%, 11.4%, 52.9%, 70% y 42.9%, respectively. We found a relationship between CDKN2A methylation and better survival (p=0.002). CDH1 methylation and poor histological differentiation (p=0.007), hMLH1 methylation and non-Mapuche ethnicity (p=0.03), APC methylation and larger tumor size (p <0.05), FHIT methylation and lack of estrogen receptor IHC expression (p <0.05). Conclusions: The high frequency of promoter methylation in patients with breast cancer confirms its role in breast carcinogenesis. The finding of alterations in the methylation pattern of genes studied and its association with prognostic factors is a helpful tool in the search of new criteria for clinical and therapeutic decision making (Rev Méd Chile 2004; 132: 1069-77)
author	Roa S,Juan Carlos Anabalón R,Leonardo Tapia E,Oscar Martínez S,Javier Araya O,Juan Carlos Villaseca H,Miguel Guzmán G,Pablo Roa E,Iván
author_facet	Roa S,Juan Carlos Anabalón R,Leonardo Tapia E,Oscar Martínez S,Javier Araya O,Juan Carlos Villaseca H,Miguel Guzmán G,Pablo Roa E,Iván
author_sort	Roa S,Juan Carlos
title	Patrón de metilación génico en el cáncer de mama
title_short	Patrón de metilación génico en el cáncer de mama
title_full	Patrón de metilación génico en el cáncer de mama
title_fullStr	Patrón de metilación génico en el cáncer de mama
title_full_unstemmed	Patrón de metilación génico en el cáncer de mama
title_sort	patrón de metilación génico en el cáncer de mama
publisher	Sociedad Médica de Santiago
publishDate	2004
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000900007
work_keys_str_mv	AT roasjuancarlos patrondemetilaciongenicoenelcancerdemama AT anabalonrleonardo patrondemetilaciongenicoenelcancerdemama AT tapiaeoscar patrondemetilaciongenicoenelcancerdemama AT martinezsjavier patrondemetilaciongenicoenelcancerdemama AT arayaojuancarlos patrondemetilaciongenicoenelcancerdemama AT villasecahmiguel patrondemetilaciongenicoenelcancerdemama AT guzmangpablo patrondemetilaciongenicoenelcancerdemama AT roaeivan patrondemetilaciongenicoenelcancerdemama
_version_	1718436166892519424

Patrón de metilación génico en el cáncer de mama

Ejemplares similares